Welcome to the Q4 2023 edition of Global Health & Pharma magazine, providing you with all of the latest news and features across the healthcare and pharmaceutical landscape. Q4 2023 As 2023 nears its end, it becomes a very fitting time to take a look back at the last 12 months and how the industry has continued to thrive. Medtech remains a very prominent concept, with organisations harnessing the power of cutting-edge technology to do incredible things. For starters, on our front cover, we’re pleased to feature the revolutionary OmniAb, our Best Therapeutic Antibody Discover Company 2023 – USA. Pushing the boundaries of therapeutic antibody discovery, OmniAb provides its pharmaceutical partners with the most diverse antibody repertoires and state-of-the-art screening technologies to facilitate the discovery of next-generation therapeutics. Elsewhere, we’re keen to promote how advancing tech has made rapid urine tests for HPV possible, an alternative method to cervical screening. A less invasive way of collecting cervical cell samples, this solution would be the ideal alternative for those who don’t wish to attend cervical screenings, in turn, saving more lives. From there, we showcase more of our award-winning firms who are also providing highly innovative solutions, whether food sensitivity and intolerance tests, prognostic diabetic biomarkers, PEMF therapy mats and devices, clinical skincare, luxury dental experiences, and many more. We also shine a light on outstanding organisations who are delivering crucial services in mental health treatment and eating disorder recovery care. I hope you find this issue to be informative and insightful, the GHP team wishes you a wonderful end to 2023 and the most prosperous quarter ahead. In the meantime, we look forward to welcoming you back again in Q1 2024. Rebecca Scotland, Editor Website: www.ghp-news.com AI Global Media, Ltd. (AI) takes reasonable measures to ensure the quality of the information on this web site. However, AI will not assume any legal liability or responsibility for the accuracy, correctness or completeness of any information that is available through this web site. If errors are brought to our attention, we will try to correct them. The information available through the website and our partner publications is for your general information and use and is not intended to address any particular finance or investment requirements. In particular, the information does not constitute any form of advice or recommendation by us or any of our partner publications and is not intended to be relied upon by users in making or refraining from making any investment or financial decisions. Appropriate independent advice should be obtained before making any such decision. Any arrangement made between you and any third party named in the site is at your sole risk and responsibility.
RkJQdWJsaXNoZXIy MTUyMDQwMA==